WO2007047692A3 - Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna - Google Patents

Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna Download PDF

Info

Publication number
WO2007047692A3
WO2007047692A3 PCT/US2006/040591 US2006040591W WO2007047692A3 WO 2007047692 A3 WO2007047692 A3 WO 2007047692A3 US 2006040591 W US2006040591 W US 2006040591W WO 2007047692 A3 WO2007047692 A3 WO 2007047692A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
systems
devices
interfering rna
small interfering
Prior art date
Application number
PCT/US2006/040591
Other languages
French (fr)
Other versions
WO2007047692B1 (en
WO2007047692A2 (en
Inventor
William F Kaemmerer
Original Assignee
Medtronic Inc
William F Kaemmerer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc, William F Kaemmerer filed Critical Medtronic Inc
Priority to EP06836357A priority Critical patent/EP1948197A4/en
Publication of WO2007047692A2 publication Critical patent/WO2007047692A2/en
Publication of WO2007047692A3 publication Critical patent/WO2007047692A3/en
Publication of WO2007047692B1 publication Critical patent/WO2007047692B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject.
PCT/US2006/040591 2005-10-19 2006-10-13 Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna WO2007047692A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06836357A EP1948197A4 (en) 2005-10-19 2006-10-13 Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/253,393 2005-10-19
US11/253,393 US7618948B2 (en) 2002-11-26 2005-10-19 Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA

Publications (3)

Publication Number Publication Date
WO2007047692A2 WO2007047692A2 (en) 2007-04-26
WO2007047692A3 true WO2007047692A3 (en) 2007-08-02
WO2007047692B1 WO2007047692B1 (en) 2007-10-18

Family

ID=37963222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040591 WO2007047692A2 (en) 2005-10-19 2006-10-13 Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna

Country Status (3)

Country Link
US (4) US7618948B2 (en)
EP (1) EP1948197A4 (en)
WO (1) WO2007047692A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10224750A1 (en) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Device for the treatment of a medical fluid
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7994149B2 (en) * 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US8680063B2 (en) * 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
ES2485848T3 (en) * 2003-09-12 2014-08-14 University Of Massachusetts RNA interference for the treatment of disorders related to function gain
JP2008503590A (en) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド Medical systems and methods for delivering compositions to cells
US7935074B2 (en) 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
US20070161591A1 (en) * 2005-08-18 2007-07-12 University Of Massachusetts Methods and compositions for treating neurological disease
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
BRPI0811623A2 (en) * 2007-05-15 2014-11-11 Helicon Therapeutics Inc METHODS FOR IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERENT RNA (SIRNA)
US8183221B2 (en) * 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
PT103865A (en) * 2007-10-25 2009-05-15 Univ De Coimbra NANO-LIPID BASIC CONVEYORS FOR DIRECT DELIVERY OF VIRAL VECTORS AND PROCESS FOR THEIR PRODUCTION
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
US20100286252A1 (en) * 2009-05-08 2010-11-11 Functional Genetics, Inc. Human fg01 gene and its applications
ES2550310T3 (en) * 2009-05-08 2015-11-06 Eli Lilly And Company Human gene fg01 and its applications
EP2453946B1 (en) 2009-07-15 2013-02-13 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
US20110052666A1 (en) * 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
WO2011087804A2 (en) 2009-12-21 2011-07-21 Medtronic, Inc. Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease
DE102010053973A1 (en) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medical device with a heater
US9694125B2 (en) 2010-12-20 2017-07-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
EP3006059B1 (en) 2011-04-21 2017-09-27 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
BR112015015258A2 (en) 2012-12-24 2017-09-26 Neurogastrx Inc Methods to Treat Gastrointestinal Tract Disorders
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
WO2015140799A1 (en) * 2014-03-18 2015-09-24 Carmel-Haifa University Economic Corp. Ltd Methods for improving cognitive function via modulation of quinone reductase 2
EP3215194A4 (en) * 2014-11-06 2018-04-04 Ibis Biosciences, Inc. Malat-1, a non-coding rna, is a target for the regulation of learning and memory
RU2020108189A (en) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. COMPOSITIONS AND METHODS OF TREATMENT OF LATERAL AMYOTROPHIC SCLEROSIS (ALS)
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
JP2019515654A (en) 2016-03-16 2019-06-13 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ Methods and compositions for treating obesity and / or diabetes, and methods and compositions for identifying candidate treatment agents
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
JP2020518258A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Amyotrophic lateral sclerosis (ALS) treatment composition and method
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US20200282019A1 (en) * 2017-07-25 2020-09-10 Dignity Health Methods of treating neurodegenerative diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5639275A (en) * 1993-08-12 1997-06-17 Cytotherapeutics, Inc. Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsules
US6180613B1 (en) * 1994-04-13 2001-01-30 The Rockefeller University AAV-mediated delivery of DNA to cells of the nervous system
US20030120282A1 (en) * 2001-12-24 2003-06-26 Scouten Charles W. Stereotaxic manipulator with retrofitted linear scales and digital display device
US20030143732A1 (en) * 2001-04-05 2003-07-31 Kathy Fosnaugh RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1229426A (en) * 1984-04-19 1987-11-17 Yutaka Harada Superconducting device
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB2181691B (en) * 1985-10-21 1990-05-23 Porvair Ltd Gloves
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
CA2109955A1 (en) 1991-05-24 1992-11-26 Toru Hayakawa Equipment for intracerebral administration of preparations
FR2685346B1 (en) 1991-12-18 1994-02-11 Cis Bio International PROCESS FOR THE PREPARATION OF DOUBLE-STRANDED RNA, AND ITS APPLICATIONS.
JPH08500481A (en) 1992-05-11 1996-01-23 リボザイム・ファーマシューティカルズ・インコーポレーテッド Methods and agents for inhibiting viral replication
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
EP1251170A3 (en) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
US5354326A (en) * 1993-01-27 1994-10-11 Medtronic, Inc. Screening cable connector for interface to implanted lead
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
WO1995016774A1 (en) * 1993-12-17 1995-06-22 Spinal Cord Society Method for inducing dna synthesis in neurons
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US6093160A (en) * 1994-11-21 2000-07-25 Augustine Medical, Inc. Flexible non-contact wound treatment device
AU4412096A (en) 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5534350A (en) * 1994-12-28 1996-07-09 Liou; Derlin Powerfree glove and its making method
AU5545596A (en) * 1995-04-28 1996-11-18 Medtronic, Inc. Intraparenchymal infusion catheter system
US7069634B1 (en) * 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5942455A (en) * 1995-11-14 1999-08-24 Drexel University Synthesis of 312 phases and composites thereof
JPH09268067A (en) * 1996-03-29 1997-10-14 Asahi Glass Co Ltd Production of silicon carbide member
ATE398459T1 (en) 1996-04-26 2008-07-15 Univ Ottawa USE OF NAIP OR IAP FOR THE TREATMENT AND PREVENTION OF NEURONAL DISEASES
WO2000062828A1 (en) 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US7189222B2 (en) * 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
US6281009B1 (en) * 1996-09-11 2001-08-28 The General Hospital Corporation Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell
US5882561A (en) * 1996-11-22 1999-03-16 Drexel University Process for making a dense ceramic workpiece
GB9701684D0 (en) * 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US5968059A (en) 1997-03-06 1999-10-19 Scimed Life Systems, Inc. Transmyocardial revascularization catheter and method
GB9706463D0 (en) * 1997-03-27 1997-05-14 Medical Res Council A model of inflamation in the central nervous system for use in the study of disease
AU7135498A (en) 1997-04-17 1998-11-11 Antivirals Inc. Method of treating restenosis by antisense targeting of cmv
US6436708B1 (en) 1997-04-17 2002-08-20 Paola Leone Delivery system for gene therapy to the brain
US5782892A (en) * 1997-04-25 1998-07-21 Medtronic, Inc. Medical lead adaptor for external medical device
US5931861A (en) 1997-04-25 1999-08-03 Medtronic, Inc. Medical lead adaptor having rotatable locking clip mechanism
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6110459A (en) 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US20050282198A1 (en) 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
EP0986373B1 (en) * 1997-06-13 2004-03-17 Nanopharm AG Drug targeting system, method of its preparation and its use
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6231969B1 (en) * 1997-08-11 2001-05-15 Drexel University Corrosion, oxidation and/or wear-resistant coatings
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6151525A (en) 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
WO1999039744A1 (en) 1998-02-10 1999-08-12 The Ohio State University Research Foundation Compositions and methods for polynucleotide delivery
DE19938960A1 (en) 1998-03-10 2001-02-22 Bisping Hans Juergen Test cable connecting probe to test apparatus, e.g. for testing implanted pacemaker, electrotherapy or electro-diagnostics includes crocodile clip and flexible conductor with spring contact
WO1999050300A1 (en) 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
US6436392B1 (en) * 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
ATE435917T1 (en) 1998-05-27 2009-07-15 Genzyme Corp AAV VECTORS FOR PRODUCING THE DRUGS FOR CONVECTION-ENHANCED ADMINISTRATION
JP2002520748A (en) 1998-07-16 2002-07-09 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク Apparatus and method for real-time volume processing and universal 3D rendering
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6585767B1 (en) 1998-11-23 2003-07-01 Agion Technologies, Inc. Antimicrobial suturing ring for heart valve
US6319905B1 (en) * 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
DE19910340A1 (en) 1999-03-09 2000-09-21 Juergen C Froelich Improved autologous venous graft
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6331427B1 (en) 1999-03-26 2001-12-18 Millennium Pharmaceuticals, Inc. Protease homologs
US6582715B1 (en) 1999-04-27 2003-06-24 Agion Technologies, Inc. Antimicrobial orthopedic implants
WO2000065042A1 (en) 1999-04-28 2000-11-02 The Board Of Trustees Of The Leland Stanford Junior University P element derived vector and methods for its use
US6310058B1 (en) 1999-05-27 2001-10-30 University Of Notre Dame Du Lac Antimycobacterial agents
WO2001016312A2 (en) 1999-08-31 2001-03-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid based modulators of gene expression
GB9928248D0 (en) 1999-12-01 2000-01-26 Gill Steven S An implantable guide tube for neurosurgery
US6310048B1 (en) * 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
US6461989B1 (en) * 1999-12-22 2002-10-08 Drexel University Process for forming 312 phase materials and process for sintering the same
US20030092003A1 (en) 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
AU2625501A (en) 1999-12-30 2001-07-16 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7276643B2 (en) 2000-02-18 2007-10-02 The Regents Of The University Of California Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
MXPA02008361A (en) 2000-02-28 2004-05-17 Genesegues Inc Nanocapsule encapsulation system and method.
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US6468524B1 (en) * 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6551290B1 (en) * 2000-03-31 2003-04-22 Medtronic, Inc. Catheter for target specific drug delivery
US6945969B1 (en) * 2000-03-31 2005-09-20 Medtronic, Inc. Catheter for target specific drug delivery
GB0009887D0 (en) 2000-04-20 2000-06-07 Btg Int Ltd Cytotoxic agents
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
WO2001091801A2 (en) 2000-05-26 2001-12-06 Chiron Corporation Methods of transducing neural cells using lentivirus vectors
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
WO2001097872A1 (en) * 2000-06-22 2001-12-27 Austin Sam L Bioadhesive compositions and methods of preparation and use
US6814014B2 (en) * 2000-07-03 2004-11-09 Brother Kogyo Kabushiki Kaisha Sewing apparatus and sewing cartridge
AU2001278951A1 (en) 2000-07-19 2002-01-30 Smith Kline Beecham Corporation Compounds and methods
EP1305074A2 (en) 2000-07-26 2003-05-02 Medtronic, Inc. Catheter for target specific drug delivery
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
AU2001288317A1 (en) * 2000-08-30 2002-03-13 Agion Technologies, Llc Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties
ES2320975T3 (en) 2000-09-11 2009-06-01 The Regents Of The University Of California PLANT NEGATIVE PLB PLB FOR USE IN THE TREATMENT OF CARDIAC DISEASES.
US6659995B1 (en) 2000-11-17 2003-12-09 Syde A. Taheri Autologous myocyte micro granual retrieval and implantation (AMMGRI)
CA2327208A1 (en) 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
US20030103945A1 (en) 2001-02-09 2003-06-05 Chen Dong Feng Methods and compositions for stimulating axon regeneration and preventing neuronal cell degeneration
US7182944B2 (en) 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US20030095958A1 (en) * 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
WO2003102131A2 (en) 2002-04-22 2003-12-11 Sirna Therapeutics Inc. Nucleic acid mediated disruption of hiv fusogenic peptide interactions
AU2002320100A1 (en) 2001-06-15 2003-01-02 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
EP1423537A4 (en) 2001-08-07 2006-11-29 Univ Delaware Compositions and methods for the prevention and treatment of huntington's disease
US6944497B2 (en) 2001-10-31 2005-09-13 Medtronic, Inc. System and method of treating stuttering by neuromodulation
AU2002249967A1 (en) 2001-11-12 2003-05-26 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
US20030105047A1 (en) 2001-11-30 2003-06-05 Medtronic, Inc. Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors
US20030120327A1 (en) 2001-12-20 2003-06-26 Mark Tobritzhofer Medical lead adaptor assembly with retainer
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
US7270653B2 (en) 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030224512A1 (en) * 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
US20040023855A1 (en) 2002-04-08 2004-02-05 John Constance M. Biologic modulations with nanoparticles
US20040018520A1 (en) 2002-04-22 2004-01-29 James Thompson Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
WO2003099298A1 (en) 2002-05-24 2003-12-04 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
US8101348B2 (en) 2002-07-10 2012-01-24 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA-interference by single-stranded RNA molecules
US7008403B1 (en) 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
AU2002368132A1 (en) 2002-07-25 2004-02-16 Nissei Kabushiki Kaisha Roll cone manufacturing device
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040032733A1 (en) * 2002-08-08 2004-02-19 Gabriel Frederick V. Candle carrier for use with candle accessories burning tea light candles
US6877447B2 (en) * 2002-08-23 2005-04-12 Tuftco Corporation Double end servo scroll and direct scroll driver pattern attachment for tufting machine
US7083620B2 (en) 2002-10-30 2006-08-01 Medtronic, Inc. Electrosurgical hemostat
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20050048641A1 (en) * 2002-11-26 2005-03-03 Medtronic, Inc. System and method for delivering polynucleotides to the central nervous system
JP2004232811A (en) 2003-01-31 2004-08-19 Hitachi Unisia Automotive Ltd Electromagnetic clutch for driving auxiliary machine
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040186528A1 (en) 2003-03-20 2004-09-23 Medtronic, Inc. Subcutaneous implantable medical devices with anti-microbial agents for chronic release
US8512290B2 (en) 2003-03-20 2013-08-20 Boston Scientific Scimed, Inc. Devices and methods for delivering therapeutic or diagnostic agents
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
SI1620133T1 (en) 2003-05-01 2016-03-31 Genzyme Corporation Gene therapy for neurometabolic disorders
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
US7917228B2 (en) 2003-05-13 2011-03-29 Medtronic, Inc. Medical lead adaptor assembly
CA2526893C (en) 2003-05-14 2010-10-26 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
US20060014165A1 (en) 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
ES2485848T3 (en) 2003-09-12 2014-08-14 University Of Massachusetts RNA interference for the treatment of disorders related to function gain
WO2005045034A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)
WO2005065242A2 (en) 2003-12-29 2005-07-21 Am Biosolutions Method of treating cancer using platelet releasate
US20050153353A1 (en) 2004-01-09 2005-07-14 Bernd Meibohm Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism
US20050202075A1 (en) * 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
WO2005116204A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2006022639A1 (en) 2004-07-21 2006-03-02 Applera Corporation Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
WO2006047250A2 (en) 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
NL1028134C2 (en) 2005-01-27 2006-07-31 Sara Lee De Nv Method for preparing a drink suitable for consumption from at least two ingredients to be dissolved and / or extracted and an amount of liquid.
TW200635542A (en) 2005-04-01 2006-10-16 Dharma Drum Mountain Method of establishing and using commemorative material
US20060257912A1 (en) 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US20080280843A1 (en) 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
GB0520235D0 (en) 2005-10-05 2005-11-16 Astrazeneca Ab Method
EP2325315B1 (en) 2005-10-28 2014-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
WO2007087451A2 (en) 2006-01-25 2007-08-02 University Of Massachusetts Compositions and methods for enhancing discriminatory rna interference
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
ITRM20060289A1 (en) 2006-05-31 2007-12-01 Ranieri Cancedda BIO MEMBRANE ENGINEERED OSTEO ANGIOGENICA AND ITS USES FOR THE REGENERATION OF BONE FABRIC
CA2662704A1 (en) 2006-07-07 2008-01-10 University Of Massachusetts Rna silencing compositions and methods for the treatment of huntington's disease
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CN200970210Y (en) 2006-10-12 2007-11-07 王会才 Cleaning and dewatering machine for mop
WO2008143774A2 (en) 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5639275A (en) * 1993-08-12 1997-06-17 Cytotherapeutics, Inc. Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsules
US6180613B1 (en) * 1994-04-13 2001-01-30 The Rockefeller University AAV-mediated delivery of DNA to cells of the nervous system
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20030143732A1 (en) * 2001-04-05 2003-07-31 Kathy Fosnaugh RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA
US20030120282A1 (en) * 2001-12-24 2003-06-26 Scouten Charles W. Stereotaxic manipulator with retrofitted linear scales and digital display device

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BASS B.L.: "RNA interference. The short answer", NATURE, vol. 411, 2001, pages 428 - 429, XP002239989 *
KENNERDELL J.R. ET AL.: "Heritable gene silencing in Drosophila using double-stranded RNA", NATURE BIOTECHNOLOGY, vol. 17, 2000, pages 896 - 898, XP002225639 *
LE GAL LA SALLE G. ET AL.: "An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain", SCIENCE, vol. 259, 1993, pages 988 - 990, XP002952043 *
LUO Y. ET AL.: "Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation", NATURE NEUROSCIENCE, vol. 4, 2001, pages 231 - 232, XP002350002 *
MENEI ET AL.: "Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres", NEUROSURGERY, vol. 34, 1994, pages 1058 - 1064, XP008127025 *
MESSIER C. ET AL.: "New techniques in stereotaxic surgery and anesthesia in the mouse", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 63, 1999, pages 313 - 318, XP003016132 *
NOORDMANS ET AL.: "Adeno-associated viral gene expression in the lateral nuclear of the rat hypothalamus", SOC. NEUROSCI. ABSTR., vol. 27, no. PROGRAM NO. 572.14, 2001, XP008127070 *
VASSAR R. ET AL.: "Beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE", SCIENCE, vol. 286, 22 October 1999 (1999-10-22), pages 735 - 741, XP002938227 *
ZLOKOVIC B.V. ET AL.: "Cellular and Molecular Neurosurgery: pathways from Concept to Reality-Part II: Vector Systems and Delivery Methodologies for Gene Therapy of the Central Nervous System", NEUROSURGERY, vol. 40, 1997, pages 805 - 813, XP002990424 *

Also Published As

Publication number Publication date
WO2007047692B1 (en) 2007-10-18
US20120093916A1 (en) 2012-04-19
WO2007047692A2 (en) 2007-04-26
US8618069B2 (en) 2013-12-31
EP1948197A2 (en) 2008-07-30
EP1948197A4 (en) 2010-01-20
US8058251B2 (en) 2011-11-15
US7618948B2 (en) 2009-11-17
US20090060987A1 (en) 2009-03-05
US20100184835A1 (en) 2010-07-22
US20060178328A1 (en) 2006-08-10
US8415319B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
WO2007047692A3 (en) Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna
WO2011053783A3 (en) Ax213 and ax132 pcsk9 antagonists and variants
WO2008057459A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2011163648A8 (en) Cns delivery of therapeutic agents
WO2008067389A3 (en) Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
WO2007022506A3 (en) Methods and compositions for treating neurological disease
EP2353651A3 (en) Use of apoptosis inhibiting compounds in degenerative neurological disorders
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2008054544A3 (en) Method for delivery across the blood brain barrier
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2006050270A3 (en) Compositions and methods for treating hyperproliferative disorders
WO2009133573A3 (en) A homeopathic formulation
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
EP1592800A4 (en) Mesecnhymal stem cells as a vehicle for ion channel transfer in syncytial structures
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
WO2004091375A3 (en) Epha2 and non-neoplastic hyperproliferative cell disorders
WO2008141308A3 (en) Gene expression and pain
WO2008076324A3 (en) Compositions and methods to treat muscular & cardiovascular disorders
WO2006080549A3 (en) Method and composition for treating central nervous system disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006836357

Country of ref document: EP